Section Arrow
Quote
ENTO.NASDAQ
- Entero Therapeutics Inc.
(Financial Status)
Quotes are at least 15-min delayed:2025/07/18 16:31 EDT
After Hours
Last
 0.4728
0 (0.00%)
Bid
0.45
Ask
0.4806
High 0.4728 
Low 0.4728 
Volume 1 
Regular Hours
Last
 0.4728
-0.0004 (-0.08%)
Day High 
0.4897 
Prev. Close
0.4732 
1-M High
0.57 
Volume 
258.02K 
Bid
0.45
Ask
0.4806
Day Low
0.4505 
Open
0.48 
1-M Low
0.361 
Market Cap 
2.26M 
Currency USD 
P/E 0.03 
%Yield -- 
10-SMA 0.47 
20-SMA 0.46 
50-SMA 0.45 
52-W High 1.11 
52-W Low 0.185 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.73/-1.74
Enterprise Value
2.31M
Balance Sheet
Book Value Per Share
-1.09
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
After Hours 2.2101 -0.0699 -3.07%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
After Hours 14.1101 +0.0351 +0.25%
NCNANuCana plc0.0477+0.0009+1.92%-- 
After Hours 0.04725 -0.00045 -0.94%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
After Hours 5.8697 +0.0297 +0.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
After Hours 5.78 -0.14 -2.36%
Quotes are at least 15-min delayed：2025/07/18 16:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.